Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03616522 · ClinicalTrials.gov registry record

A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer

A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
25
Enrollment target

NCT03616522: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.

NCT03616522 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03616522 has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
25 participants
Enrollment target

Study Summary

Symptoms are common among patients with advanced malignancy undergoing treatment, and yet often go unrecognized by treatment providers. In addition to contributing to morbidity, poorly controlled symptoms drive emergency room utilization and hospital admission in this population, representing significant cost to patients, families, and the health care system. Systematic collection of patient-reported outcomes (PROs) has been proposed as a way to arm providers with the information necessary to intervene early, intensify symptom management, and improve symptom control. Recent research suggests that a standardized, web-based program of weekly patient-reported symptom monitoring leads to improved health-related quality of life and reduced acute care utilization; it may also prolong overall survival. Despite mounting evidence supporting its use among oncology patients, systematic PRO collection is lacking at most cancer centers, and optimal models for collection of PROs are poorly understood. The objective of this study is to evaluate prospectively the feasibility of a novel mobile phone-based intervention of weekly symptom reporting, among patients undergoing treatment for advanced non-small cell lung cancer.

Primary Outcome

evaluate subjects to study-level adherence of a mobile phone-based intervention for automated PRO collection

Interventions

  • OTHER a novel mobile phone-based intervention for automated electronic PRO collection

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-05-21
Est. Completion 2019-02-18

What the finished NCT03616522 record still lists

NCT03616522 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which a novel mobile phone-based intervention for automated electronic PRO collection is the first listed.

NCT03616522 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03616522 about?

NCT03616522 is a clinical study titled "A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer". Symptoms are common among patients with advanced malignancy undergoing treatment, and yet often go unrecognized by treatment providers. In addition to contributing to morbidity, poorly controlled symptoms drive emergency room utilization and hospital admission in this population, representing signif...

What is the current status of trial NCT03616522?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-05-21. Estimated completion is 2019-02-18.

What interventions are being tested in trial NCT03616522?

The interventions under investigation include: a novel mobile phone-based intervention for automated electronic PRO collection (OTHER).

Who is sponsoring clinical trial NCT03616522?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03616522, the US trial registry maintained by the National Library of Medicine. NCT03616522 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.